Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications

Elina Alaterre, Nicolas Robert, Guilhem Requirand, Amélie Machura, Hugues De Boussac, Laure Vincent, Charles Herbaux, Angélique Bruyer, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 4743.

https://doi.org/10.1182/blood-2023-181767

Published: 2023

Journal Articles

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Clementine Sarkozy, Thierry Jo Molina, Roch Houot, Sydney Dubois, Gian Matteo Pica, Philippe Ruminy, Charles Herbaux, Thomas Gastinne, Corinne Haioun, Stephanie Guidez, Christophe Bonnet, Marc Andre, Liana Vereseza, Choquet Sylvain, Loic Ysebaert, Emmanuel Bachy, Fabrice Jardin, Franck Morschhauser, Vincent Ribrag

Blood (2023) 142 (Supplement 1): 853.

https://doi.org/10.1182/blood-2023-174607

Published: 2023

Journal Articles

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Blood (2023) 142 (Supplement 1): 2140.

https://doi.org/10.1182/blood-2023-185632

Published: 2023

Journal Articles

Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology

Emmanuel Varlet, Elina Alaterre, Morgane Thomas, Hugues De Boussac, Laure Vincent, Guillaume Cartron, Charles Herbaux, Caroline Bret, Laurie Herviou, Anne Marie Martinez, Christophe Hirtz, Aurore Attina, Jerome Vialaret, Giacomo Cavalli, Jerome Moreaux, Sara Ovejero

Blood (2023) 142 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2023-181018

Published: 2023

Journal Articles

Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma

Alizée Steer, Elina Alaterre, Djamila Chamlal, Emmanuel Varlet, Amélie Machura, Alboukadel Kassambara, Guilhem Requirand, Nicolas Robert, Laure Vincent, Charles Herbaux, Hugues De Boussac, Angélique Bruyer, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2023-180877

Published: 2023

Journal Articles

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Luca Inchiappa, Lise Willems, Jérôme Paillassa, Charles Herbaux, Cecile Tomowiak, Anne Lok, Diane Lara, Bijou Fontanet, Urbain Tauveron-Jalenques, Antoine Ittel, Adrien Caillet, Norbert Vey, Xavier Troussard

Blood (2023) 142 (Supplement 1): 6170.

https://doi.org/10.1182/blood-2023-186971

Published: 2023

Journal Articles

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Blood (2023) 142 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2023-178623

Published: 2023

Journal Articles

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Andrew D. Zelenetz, Catherine S. Diefenbach, Charles Herbaux, Monica Tani, Roch Houot, Mariana Bastos-Oreiro, Herve Tilly, Thomas Gastinne, Catherine Thieblemont, Ethan Troy-Barnes, Stefano Olivieri, Murali Kesavan, Manisha Kanwar, Simona Barlera, Katerina Hatzi, Yanwen Jiang, Michelle Boyer, Franck Morschhauser

Blood (2023) 142 (Supplement 1): 439.

https://doi.org/10.1182/blood-2023-174855

Published: 2023

Journal Articles

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Elvira Garcia De Paco, Caroline Soulet, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Laure Vincent, Charles Herbaux, Maria Moriel-Carretero, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 3322.

https://doi.org/10.1182/blood-2023-181039

Published: 2023

Journal Articles

Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression

Benoît Tisserand, Caroline Bret, Yassine Al Tabaa, Sylvain Lamure, Xavier Ayrignac, Laura Platon, Patrice Ceballos, Ludovic Gabellier, Jerome Moreaux, Charles Herbaux, Guillaume Cartron, Jean-Jacques Tudesq

Blood (2023) 142 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2023-185520

Published: 2023

Journal Articles

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Laure Dutrieux, Elle Loughran, Armelle Choquet, Hélène Herault, Antoine Guillemin, Nicolas Robert, Guilhem Requirand, Guillaume Cartron, Laure Vincent, Charles Herbaux, Eric Rivals, Alexandre David, Jerome Moreaux

Blood (2023) 142 (Supplement 1): 1924.

https://doi.org/10.1182/blood-2023-184749

Published: 2023

Journal Articles

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Xavier Phina-Ziebin, Emmanuel Bachy, Francois Xavier Gros, Roberta Di Blasi, Charles Herbaux, Jacques-Olivier Bay, Sylvain Carras, Pierre Bories, René-Olivier Casasnovas, Fabrice Jardin, Franck Morschhauser, Blandine Guffroy, Elodie Gat, Julien Calvani, Marie Parrens, Elsa Poullot, Alexandra Traverse-Glehen, Louise Roulin

Blood (2023) 142 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2023-180707

Published: 2023

Journal Articles

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Blood (2022) 140 (Supplement 1): 1485–1487.

https://doi.org/10.1182/blood-2022-157399

Published: 2022

Journal Articles

Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma

Sara ovejero-Merino, Julie Devin, Tatiana Cañeque, Laura Alibert, Guilhem Requirand, Nicolas Robert, Alizée Steer, Amelie Machura, Christophe Hirtz, Angélique Bruyer, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Caroline Bret, Jerome Moreaux

Blood (2022) 140 (Supplement 1): 9980–9981.

https://doi.org/10.1182/blood-2022-163252

Published: 2022

Journal Articles

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 1859–1861.

https://doi.org/10.1182/blood-2022-167840

Published: 2022

Journal Articles

Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, Lise Willems, Fatiha Merabet, Charles Herbaux, Damien Roos Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, Ronan Le Calloch, Benoit Bareau, Marie C Béné, Veronique Leblond

Blood (2022) 140 (Supplement 1): 3627–3628.

https://doi.org/10.1182/blood-2022-157394

Published: 2022

Journal Articles

Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Sara ovejero-Merino, Laura Alibert, Julie Devin, Tatiana Cañeque, Ouissem Karmous Gadacha, Matthieu Abouladze, Guilhem Requirand, Nicolas Robert, Hugues De Boussac, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Jerome Moreaux, Caroline Bret

Blood (2022) 140 (Supplement 1): 6439–6440.

https://doi.org/10.1182/blood-2022-164644

Published: 2022

Journal Articles

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Blood (2022) 140 (Supplement 1): 1297–1300.

https://doi.org/10.1182/blood-2022-157559

Published: 2022

Journal Articles

EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Guilhem Requirand, Nicolas Robert, Elina Alaterre, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angélique Bruyer, Hugues De Boussac, Jerome Moreaux

Blood (2022) 140 (Supplement 1): 4220–4221.

https://doi.org/10.1182/blood-2022-163261

Published: 2022

NARROW

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Integrative Multi-Omics Analysis of Tumor-Immune Microenvironment in Multiple Myeloma: Novel Insights and Therapeutic Implications

Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study

Invasive Fungal Infections after CAR T-Cell Therapy for B-Cell Lymphoma: A Study from the French Descart Registry

Epigenetic Modifiers MMSET and EZH2 Physically Interact and Cooperate to Support Multiple Myeloma Pathophysiology

Characterization of a New Metabolic Score Correlated with CD38 Cell-Surface Expression and Response to Daratumumab Treatment in Multiple Myeloma

Efficacy of Chemo-Free Combination Therapy with BRAF Inhibitor and Rituximab in Classic Hairy Cell Leukemia: Insights from the French Experience

Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Lipid-Mediated Modulation of DNA Damage Signaling As a Prognostic and Therapeutic Strategy Against Multiple Myeloma

Early Progressions of Undetermined Significance (EPUS) in the Month Following CAR-T Cells for B-Cell NHL Is Mainly Related to Pseudoprogression

Translation Inhibition through eIF4A1 Targeting in Multiple Myeloma Is a Promising Therapeutic Strategy

Outcomes of High-Grade B-Cell Lymphoma As Compared to Other Large B-Cell Lymphoma Subtypes in Patients Treated with CD19-Directed CAR-T Cells at 3 rd Line or More. a Lysa Study Based on the French Descart-Registry.

Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)

Targeting Iron Homeostasis As a Therapeutic Strategy in Multiple Myeloma

Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry

Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Ironomycin Induces Mantle Cell Lymphoma Cell Death By Targeting Iron Metabolism Addiction

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

EZH2 Targeting Induces CD38 Upregulation and Response to Anti-CD38 Antibodies in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only